<DOC>
	<DOCNO>NCT01597297</DOCNO>
	<brief_summary>The objective study Multiple Sclerosis ( MS ) participant treat prolonged-released fampridine ( BIIB041 ) 10 mg twice daily compare participant treat placebo ass effect 24 week follow parameter explore endpoint Phase 3 study : self-assessed walking disability , dynamic static balance , subjective impression well-being , participant ' global impression change walking . Another purpose study evaluate safety tolerability prolonged-release fampridine .</brief_summary>
	<brief_title>Exploratory Study Assess Effect Fampridine ( BIIB041 ) Walking Ability Balance Participants With Multiple Sclerosis .</brief_title>
	<detailed_description>The primary objective study explore effect prolonged-released fampridine 10 mg twice daily patient Multiple Sclerosis walking disability . The change walk ability measure use Multiple Sclerosis Walking Scale-12 ( MSWS-12 ) elucidate clinical relevance change 24 week treatment duration . Another purpose study evaluate safety tolerability prolonged-release fampridine . Approximately 120 patient MS randomize 20 site worldwide . Duration patient 's participation study approximately 28 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Key Must able understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation Diagnosis primaryprogressive , secondary progressive , progressiveremitting , relapsingremitting Multiple Sclerosis least 3month duration EDSS 4 7 Female patient childbearing potential must practice effective contraception study willing able continue contraception 30 day last dose study treatment Must able understand comply requirement protocol Key Known allergy pyridinecontaining substance inactive ingredient prolong release fampridine ( BIIB041 ) tablet Any history seizure , epilepsy , convulsive disorder , exception febrile seizures childhood An estimate creatinine clearance ( CrCl ) &lt; 80 mL/minute ( use CockcroftGault formula ) Known history Human Immunodeficiency Virus , hepatitis C , hepatitis B . Subjects evidence prior hepatitis infection serologically confirm resolve base previous test documented subject ' medical history exclude study participation History malignant disease include solid tumor hematologic malignancy ( exception basal cell squamous cell carcinoma skin completely excise consider cure ) within 5 year prior Screening Visit , time screen period Onset MS exacerbation within 60 day prior Screening Visit , time screening period History major surgical intervention ( exception skin biopsy ) within 30 day prior Screening Visit , time screen period Any nonMSrelated condition factor ( determined Investigator ) likely interfere walk ability include , limited , previous major surgery foot , leg , hip ; significant trauma ; know peripheral neuropathy low limb Presence pulmonary disease include , limited , chronic obstructive pulmonary disease could impede subject 's daily activity ( determine Investigator ) Presence psychiatric disorder , include clinical depression , likely interfere subject 's participation study ( determined Investigator ) Uncontrolled hypertension ( determined Investigator ) Screening Visit , time screening period , Day 1 History clinically significant endocrinologic , hematologic , immunologic , metabolic , urologic , neurologic ( except MS , include event indicative potentially low seizure threshold ) , dermatologic , major disease ( determined Investigator ) Clinically significant abnormal laboratory value ( determine Investigator ) A Body Mass Index ≥40 Use label MS treatment include rituximab , alemtuzumab , daclizumab , antibody ( except natalizumab ) within 3 month prior Screening Visit , time screening period , schedule use study participation Use mitoxantrone cyclophosphamide within 3 month prior Screening Visit , time screening period , schedule use study participation Initiation natalizumab treatment change subject 's dose regimen natalizumab , within 3 month prior Screening Visit , time screen period Initiation treatment , change subject 's dose regimen , interferon β 1b , interferon β1a , fingolimod , glatiramer acetate within 30 day prior Screening Visit , time screen period Pulsed steroid treatment within 60 day prior Screening Visit , time screen period Any change subject 's medication dose regimen treatment fatigue depression within 30 day prior Screening Visit , time screen period Any change prophylactic treatment pain antidepressant anticonvulsant prescribe purpose within 30 day prior Screening Visit , time screen period Any change subject 's dose regimen antispastic agent within 7 day prior Screening Visit , time screening period Treatment investigational drug approve therapy investigational use within 30 day ( 7 halflives , whichever long ) prior Screening Visit , time screening period Treatment 4AP 3,4diaminopyridine ( DAP ) formulation within 30 day prior Screening Visit , time screening period History drug alcohol abuse ( define Investigator ) within 2 year prior Screening Visit , time screen period Female subject currently pregnant consider become pregnant participate study . Female subject childbearing potential positive pregnancy test either Screening Visit Day 1 may participate study Female subject currently breastfeed Inability comply study requirement Current enrollment drug , biological , device , clinical study Previous participation study Any reason , opinion Investigator , would disqualify subject participation study make subject unsuitable enrollment NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>